Slow Capital Inc. Reduces Holdings in Moderna, Inc. (NASDAQ:MRNA)

Slow Capital Inc. lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 14.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,253 shares of the company’s stock after selling 4,484 shares during the quarter. Slow Capital Inc.’s holdings in Moderna were worth $1,821,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC acquired a new position in Moderna during the 2nd quarter valued at approximately $26,000. Family Firm Inc. purchased a new position in Moderna in the 2nd quarter worth $33,000. Cedar Wealth Management LLC lifted its position in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the period. Westside Investment Management Inc. purchased a new stake in Moderna during the 1st quarter valued at about $32,000. Finally, Bank & Trust Co acquired a new position in shares of Moderna in the second quarter valued at about $36,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and decreased their target price for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. JPMorgan Chase & Co. downgraded shares of Moderna from a “neutral” rating to an “underweight” rating and dropped their price objective for the company from $88.00 to $70.00 in a report on Friday, September 13th. Bank of America reduced their target price on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a report on Friday, September 13th. Piper Sandler lowered their price target on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, September 13th. Finally, Jefferies Financial Group cut their price target on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $97.18.

Moderna Trading Down 1.3 %

Shares of MRNA stock opened at $54.10 on Friday. Moderna, Inc. has a fifty-two week low of $53.55 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The stock’s fifty day moving average is $70.75 and its two-hundred day moving average is $104.56. The firm has a market capitalization of $20.73 billion, a P/E ratio of -3.45 and a beta of 1.66.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. The business had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company’s quarterly revenue was down 29.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($3.62) earnings per share. Research analysts expect that Moderna, Inc. will post -9.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $119.96, for a total value of $1,799,400.00. Following the completion of the sale, the director now directly owns 2,224,015 shares in the company, valued at $266,792,839.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $119.96, for a total transaction of $1,799,400.00. Following the transaction, the director now owns 2,224,015 shares of the company’s stock, valued at approximately $266,792,839.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,184 shares of company stock valued at $3,804,931 in the last ninety days. 15.70% of the stock is currently owned by corporate insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.